Clinical Trial Update: Detection of Factor V Leiden G1691A and Factor II (Prothrombin) G20210A Point Mutations in DNA

View source ↗

Summary

A completed clinical trial focused on detection and genotyping of Factor V Leiden G1691A and Factor II (prothrombin) G20210A point mutations in DNA.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thrombophilia
• Venous Thromboembolism

Snippet

Sponsor: Illumina, Inc. | Conditions: Detection and Genotyping of Factor V and Factor II Point Mutations | Status: COMPLETED